IXC - Invex TherapeuticsThis company is a Phase 3 ORPHAN bio focusing in on IIH.
They have 31 mill cash on hand which will fully fund them all the way. They are currently valued at 40 mill MC so essentially 9 mill EV which is ridiculous for a Phase 3 bio.
Putting in a bottoming pattern now with a reverse head and shoulders
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.022 AUD
−1.64 M AUD
0.00 AUD
74.85 M
About INVEX THERAPEUTICS LTD
Sector
Industry
Headquarters
Subiaco
Website
Founded
2019
ISIN
AU0000048621
FIGI
BBG00PD615S3
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses on understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.
$IXC - INVEX THERAPEUTICS - New ASX listingInvex Therapeutics aims to re-purpose a diabetic drug for brain disorders such as idiopathic intracranial hypertension, traumatic brain injury and acute stroke.
It only just listed but seems to be headed the right way price wise. It is already up another 16% today with 99 buyers for 659,825 units v
INVEX TH$IXC $IXC.AX - breaking above resistance - LONGInvex Therapeutics aims to re-purpose a diabetic drug for brain disorders such as idiopathic intracranial hypertension, traumatic brain injury and acute stroke. As the product is already in production and use there is an easy route to entry.
Sector: Healthcare
Industry: Pharmaceuticals
Supply is b
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IXC is 0.076 AUD — it hasn't changed in the past 24 hours. Watch INVEX THERAPEUTICS LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange INVEX THERAPEUTICS LTD stocks are traded under the ticker IXC.
IXC stock has fallen by −5.00% compared to the previous week, the month change is a −7.32% fall, over the last year INVEX THERAPEUTICS LTD has showed a −66.96% decrease.
IXC stock is 0.00% volatile and has beta coefficient of 0.76. Track INVEX THERAPEUTICS LTD stock price on the chart and check out the list of the most volatile stocks — is INVEX THERAPEUTICS LTD there?
Today INVEX THERAPEUTICS LTD has the market capitalization of 5.71 M, it has decreased by −5.00% over the last week.
Yes, you can track INVEX THERAPEUTICS LTD financials in yearly and quarterly reports right on TradingView.
INVEX THERAPEUTICS LTD is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
IXC net income for the last half-year is 470.89 K AUD, while the previous report showed −2.11 M AUD of net income which accounts for 122.29% change. Track more INVEX THERAPEUTICS LTD financial stats to get the full picture.
Like other stocks, IXC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INVEX THERAPEUTICS LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INVEX THERAPEUTICS LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INVEX THERAPEUTICS LTD stock shows the sell signal. See more of INVEX THERAPEUTICS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.